BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 31695765)

  • 21. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
    Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
    Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.
    Zheng B; Liu XL; Fan R; Bai J; Wen H; Du LT; Jiang GQ; Wang CY; Fan XT; Ye YN; Qian YS; Wang YC; Liu GJ; Deng GH; Shen F; Hu HP; Wang H; Zhang QZ; Ru LL; Zhang J; Gao YH; Xia J; Yan HD; Liang MF; Yu YL; Sun FM; Gao YJ; Sun J; Zhong CX; Wang Y; Kong F; Chen JM; Zheng D; Yang Y; Wang CX; Wu L; Hou JL; Liu JF; Wang HY; Chen L
    Clin Cancer Res; 2021 Jul; 27(13):3772-3783. PubMed ID: 33947693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study.
    Lewin J; Kottwitz D; Aoyama J; deVos T; Garces J; Hasinger O; Kasielke S; Knaust F; Rathi P; Rausch S; Weiss G; Zipprich A; Mena E; Fong TL
    BMC Gastroenterol; 2021 Mar; 21(1):136. PubMed ID: 33765926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma.
    Elzehery R; Effat N; El Farahaty R; Elsayed Farag R; Abo-Hashem EM; Elhelaly R
    Am J Clin Pathol; 2022 Aug; 158(2):254-262. PubMed ID: 35403666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
    Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
    J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and validation of DNA hypomethylation biomarkers for liver cancer using HRM-specific probes.
    Stefanska B; Bouzelmat A; Huang J; Suderman M; Hallett M; Han ZG; Al-Mahtab M; Akbar SM; Khan WA; Raqib R; Szyf M
    PLoS One; 2013; 8(8):e68439. PubMed ID: 23950870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma.
    Lin SY; Xia W; Kim AK; Chen D; Schleyer S; Choi L; Wang Z; Hamilton JP; Luu H; Hann HW; Chang TT; Hu CT; Woodard A; Gade TP; Su YH
    Sci Rep; 2023 Dec; 13(1):21585. PubMed ID: 38062093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
    Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
    Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
    Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
    Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma.
    Holmila R; Sklias A; Muller DC; Degli Esposti D; Guilloreau P; Mckay J; Sangrajrang S; Srivatanakul P; Hainaut P; Merle P; Herceg Z; Nogueira da Costa A
    PLoS One; 2017; 12(3):e0174265. PubMed ID: 28333958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?
    Jeepalyam S; Sheel A; Ejaz A; Miller E; Manne A
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients.
    Ren J; Lu P; Zhou X; Liao Y; Liu X; Li J; Wang W; Wang J; Wen L; Fu W; Tang F
    Clin Chem; 2022 Feb; 68(2):354-364. PubMed ID: 34791072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.
    Chen K; Zhang H; Zhang LN; Ju SQ; Qi J; Huang DF; Li F; Wei Q; Zhang J
    World J Gastroenterol; 2013 May; 19(20):3143-9. PubMed ID: 23716996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 38. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development.
    Lubecka K; Flower K; Beetch M; Qiu J; Kurzava L; Buvala H; Ruhayel A; Gawrieh S; Liangpunsakul S; Gonzalez T; McCabe G; Chalasani N; Flanagan JM; Stefanska B
    Epigenetics; 2018; 13(6):605-626. PubMed ID: 29927686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of DNA methylation signatures for hepatocellular carcinoma detection and microvascular invasion prediction.
    Hao Y; Yang Q; He Q; Hu H; Weng Z; Su Z; Chen S; Peng S; Kuang M; Chen Z; Xu L
    Eur J Med Res; 2022 Dec; 27(1):276. PubMed ID: 36464701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.